What do prescribers think of biosimilars?

Targeted Oncology

Volumn 7, Issue SUPPL.1, 2012, Pages

  Aapro, M S ^a  

^a CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Biosimilars; Erythropoietins; Generic drugs; Growth factors; Prescription

Indexed keywords

ANTINEOPLASTIC AGENT; BIOSIMILAR AGENT; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANTINEOPLASTIC ACTIVITY; COMMUNITY; DRUG ACTIVITY; DRUG APPROVAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG MANUFACTURE; DRUG POTENCY; DRUG QUALITY; DRUG SAFETY; HUMAN; PATENT; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL AGENTS; DRUG PRESCRIPTIONS; DRUGS, GENERIC; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION;

EID: 84857903642     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0193-6     Document Type: Review

References (26)

1. Schellekens H, Klinger E, Mühlebach S, et al. (2011) The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol 59:176-83
2. Dupont AG, Heller F (2009) Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence? Acta Clin Belg 64:406-14
3. Genazzani AA, Pattarino F (2008) Difficulties in the production of identical drug products from a pharmaceutical technology viewpoint. Drugs R D 9:65-72 (Pubitemid 351311220)
4. Margolese HC, Wolf Y, Desmarais JE, Beauclair L (2010) Loss of response after switching from brand name to generic formulations: three cases and a discussion of key clinical considerations when switching. Int Clin Psychopharmacol 25(3):180-2
5. Del Tacca M, Pasqualetti G, Di Paolo A et al (2009) Lack of pharmacokinetic bioequivalence between generic and branded amoxicillin formulations. A post-marketing clinical study on healthy volunteers. Br J Clin Pharmacol 68:34-42
6. Decollogny A, Eggli Y, Halfon P, Lufkin TM (2011) Determinants of generic drug substitution in Switzerland. BMC Health Serv Res 11:17
7. Mellstedt H, Niederwieser D, Ludwig H (2008) The challenge of biosimilars. Ann Oncol 19:411-9 (Pubitemid 351325660)
8. Schellekens H, Moors E (2010) Clinical comparability and European biosimilar regulations. Nat Biotechnol 28(1):28-31
9. EMEA. Questions and Answers on biosimilar medicines (similar biological medicinal products). 〈http://www.ema.europa.eu/pdfs/human/pcwp/7456206en. pdf.2008〉[last accessed: 8th March 2011]
10. Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8-32
11. www.ema.europa.eu/docs/en-GB/document-library/Public-statement/2009/11/ WC500011292.pdf [last accessed March 16, 2011]
12. Brockmeyer C, Seidl A (2009) Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals. Eur J Hosp Pharm Prac 15(2):34-40
13. Schellekens H (2009) Assessing the bioequivalence of biosimilars: the Retacrit® case. Drug Discov Today 14(9-10):495-9
14. Falandry C, Campone M, Cartron et al (2010) Trends in G-CSF use in 990 patients after EORTC and ASCO guidelines. Eur J Cancer 46:2389-98
15. Almenar D, Mayans D, Juan O et al (2009) Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN study. Eur J Cancer Care 18:280-6
16. Weycker D, Hackett J, Edelsberg J et al (2006) Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother 40:402-7
17. Aapro M, Van Erps J, MacDonald K et al (2009) Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study. Eur J Cancer 45 (1):8-11
18. Aapro M, Van Erps J, MacDonald K et al (2008) Promoting evidence-based management of anemia in cancer patients: background, development, and scientific validation of RESPOND, a web-based clinical guidance system based on the EORTC guidelines. Crit Rev Oncol Hematol 65:32-42 (Pubitemid 350225667)
19. Van Erps J, Aapro M, McDonald K et al (2010) Promoting evidence-based management of anemia in cancer patients: concurrent and discriminant validity of RESPOND, a web-based clinical guidance system based on the EORTC guidelines for supportive care in cancer. Support Care Cancer 18:847-58
20. Gascón P, Aapro M, Ludwig H et al (2011) Background and methodology of MONITOR-GCSF, a pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Crit Rev Oncol Hematol 77:184-97
21. Gascón P, Aapro M, Ludwig H et al (2011) Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. Crit Rev Oncol Hematol 77:198-200
22. Rizzo JD, Brouwers M, Hurley P et al (2010) American Society of Clinical Oncology/ American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28:4996-5010
23. Schrijvers D, De Samblanx H, Roila F, ESMO Guidelines Working Group (2010) Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21(Suppl 5):v244-v7
24. Kanavos P (2007) Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin 23:105-16
25. Godman B, Shrank W, Andersen M et al (2010) Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharmacoecon Outcomes Res 10:707-22
26. Aapro M, Cornes P, Abraham I (2011) Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract [in press]